Semaglutide halts osteoblast ferroptosis and alveolar bone loss in diabetic periodontitis mice

Type 2 diabetes mellitus (T2DM) significantly elevates the risk and severity of periodontitis, a chronic inflammatory disease leading to progressive alveolar bone loss. This bone destruction is exacerbated in diabetic patients, often due to impaired osteoblast function. Ferroptosis, a distinct iron-dependent form of regulated cell death, has emerged as a critical contributor to osteoblast dysfunction under high glucose and lipid conditions. Understanding and targeting this pathway, particularly the non-canonical Wnt5a/Ror2 pathway, represents a crucial gap in developing effective treatments for diabetic periodontitis.

This preclinical study investigated the effects of semaglutide on osteoblast ferroptosis in a T2DM mouse model of ligature-induced periodontitis. While specific doses and treatment durations were not detailed in the abstract, the intervention aimed to counteract the effects of high glucose and high lipid (HGHP) conditions. Alveolar bone integrity was assessed using H&E staining. Key ferroptosis-related markers, including OPN (osteopontin), GPX4 (glutathione peroxidase 4), and 4-HNE (4-hydroxynonenal), were evaluated via immunohistochemistry and immunofluorescence to quantify osteoblast health and oxidative stress. The study also explored the involvement of the Wnt5a/Ror2/p38 MAPK signaling pathway.

In vitro, high glucose and high lipid (HGHP) conditions were found to induce osteoblast ferroptosis and significantly increase oxidative stress. In the in vivo model, semaglutide treatment effectively inhibited osteoblast ferroptosis and reduced alveolar bone loss in T2DM mice with periodontitis. The intervention also reversed the increase in oxidative stress markers associated with diabetic conditions. While specific quantitative data (e.g., percentages, p-values) were not provided in the abstract, the findings consistently pointed to a protective effect. > Semaglutide modulated the Wnt5a/Ror2/p38 MAPK signaling pathway, indicating its involvement in the observed ferroptosis inhibition. Immunohistochemistry revealed altered expression of OPN and GPX4, and 4-HNE immunofluorescence indicated changes in lipid peroxidation, all consistent with the suppression of ferroptosis. These results suggest a direct mechanism by which semaglutide protects osteoblasts from diabetic damage.